UNSPSC 51171814: Dolasetron

This classification denotes a 5-ht3 receptor antagonist and antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82WI2L7Q6E. European Medicines Agency schedules Dolasetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06352MIG. Dolasetron generally arises in the molecular formula C19H20N2O3. The term DOLASETRON is an International Non-Proprietary Name or INN. DOLASETRON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule dolasetron under HS 29339990 and SITC 51577. As of Q4 2014, DOLASETRON remains the US FDA Preferred Term for this commodity. Dolasetron bears US NLM identifiers UMLS ID C0209210 and NCI Concept Code C61735. SMILES: O(C1CC2N3C(CC(C2)C(=O)C3)C1)C(=O)C1C2C([NH]C1)CCCC2.

UNSPSC 51171814 Dolasetron, a Commodity code, represents pharmaceutical products purchased by state and local health agencies, corrections departments, and cooperative purchasing alliances for clinical use in detention, hospital, and public health settings. The code encompasses specific antiemetic medications supplied through established pharmaceutical distribution channels and cooperative purchasing frameworks that aggregate demand across multiple jurisdictions. State and local buyers under this code include corrections departments managing inmate health services, state health and human services agencies, and multistate cooperative purchasing organizations that negotiate volume contracts with manufacturers and authorized wholesalers for distribution to participating state agencies, local governments, and other public entities.

Recent activity reflects two distinct procurement patterns. Collin County Community Supervision and Corrections Department issued RFP 2026-327 (due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026) for offender specimen collection and drug testing services—a scope that does not directly align with pharmaceutical procurement under the Dolasetron code. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted March 27, 2026, response due April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, which explores pharmaceutical supply chain models but does not specify individual products. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota, Oregon, and other participating jurisdictions, with awarded vendors effective July 1, 2026 and a two-year initial term. The code shows little relevant recent activity tied explicitly to Dolasetron procurement; the opportunities in the record address broader pharmaceutical supply, drug testing services, and cooperative purchasing frameworks rather than specific antiemetic medications.